Funding · last 3 months
Waiting for Compass
Live medtech trackerJump to section:
Live updates powered by Compass AI
Real-time global intelligence on private companies, funding, and more insights sourced from LSI's primary research and three global summits.
Funding · last 3 months
Waiting for Compass
Funding · last 12 months
Waiting for Compass
Deals · last 3 months
Waiting for Compass
Deals · last 12 months
Waiting for Compass
Explore the full Compass AI platform to source and close your next investment, acquisition, partner or customer.
Surgery · Funding · last 3 months
Waiting for Compass
Surgery · Funding · last 12 months
Waiting for Compass
Surgery · Deals · last 3 months
Waiting for Compass
Surgery · Deals · last 12 months
Waiting for Compass
Chart preview — not live figures yet
Live Compass data is loading
See the full platform with every company, deal, investor and signal behind this tracker and beyond.
Live Compass data is loading
Live Compass data is loading
Explore every company, deal, investor and signal behind this tracker in the full platform.
Live Compass data is loading
Live Compass data is loading
See which investors are actively writing checks in your market and stage.
Chart preview — not live figures yet
Live Compass data is loading
Live Compass data is loading
Oct 18, 2026Resonant Link Medical is expanding what's possible for implantable devicesProfile of CEO Omari Bouknight
Oct 16, 2026LSI alumni achievements driving medtech and healthtech forwardMilestones from CMR Surgical, Nami Surgical and more
Oct 11, 2026Chipiron is rebuilding MRI from first principlesProfile of co-founder and CEO Evan KervellaNo rounds match these filters. Try a longer time window.
Gilead agreed to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including lead asset HCXT-2001.
China’s NMPA approved Galderma’s Relfydess for temporary improvement of moderate-to-severe frown lines in adults.
Biovica’s rights issue was fully subscribed, with about 71.11% taken up by shareholders and the remaining 28.89% allocated to guarantor HDF Cancer Monitoring.
The FDA granted 510(k) clearance for BoneEnhance, a machine learning software module for RIVANNA’s Accuro XV diagnostic ultrasound system.
Lucid Diagnostics began receiving Medicare payments for its EsoGuard Esophageal DNA Test.
Teleflex received FDA breakthrough device designation for its Freesolve resorbable magnesium scaffold for use in percutaneous coronary intervention.
Scanbo's D-Series devices combine vital-sign measurements and blood glucose testing in a portable system.
Aclarion announced publication of an independent, peer-reviewed study evaluating Nociscan against provocative discography for identifying painful lumbar discs.
No venture or corporate venture investors in this window.
No acquisitions match these filters.
No exits in this window.
Headline stats are not available for this window.
Funding activity is not available.
— M&A— IPOsSince Q1 2023
Exit activity is not available.
Market totals are not available right now.
The largest listed medtech companies, with AI summaries of the news moving each stock.
Medical-device stocks averaged a 0.24% decline. Intuitive Surgical (+1.90%) and Abbott (+1.16%) led the gainers, while Johnson & Johnson (-1.42%) and Baxter (-1.36%) had the largest declines.
No headline was supplied for Johnson & Johnson. Its shares fell 1.42%.
No headline was supplied for Abbott. Its shares rose 1.16%.
No headline was supplied for Danaher. Its shares rose 0.33%.
No headline was supplied for Intuitive Surgical. Its shares rose 1.90%.
No headline was supplied for Medtronic. Its shares fell 1.22%.
No headline was supplied for Stryker. Its shares rose 0.02%.